Incubate Releases Statement on Trump Administration's "Most Favored Nation" Pricing Deal

WASHINGTON (Sep 30) -- Today, the Trump administration announced its first agreement with a manufacturer to bring most-favored-nation drug pricing to American patients.

Incubate's executive director, John Stanford, issued the following statement:

"While we appreciate the Trump administration's focus on addressing international freeloading and ensuring other countries pay their fair share, we remain concerned about the broader threats to innovation that these negotiations may bring, especially to early-stage innovators that do not have any product revenues and are thus solely reliant on investors to bring their treatments to market.

"Drug development is an expensive, risky, and sometimes decades-long process. Price controls of any kind deter the massive venture investments needed to pursue the groundbreaking innovation our industry has become known for. As we have consistently warned, the MFN model could delay the arrival of innovative treatments for patients who need them most.

"Incubate remains committed to educating policymakers about the broader biotech ecosystem that patients depend on. We will continue to monitor developments in the coming days and weeks as more pharmaceutical companies respond."

###

About Incubate

Incubate is a 501(c)(4) organization of venture capital firms representing the patient, corporate, and investment communities. Our primary aim is to educate policymakers on the role of venture capital in bringing promising treatments to patients in need.